Skip to main content

Table 1 Baseline clinical characteristics

From: Low dose of mycophenolate mofetil is enough in desensitized kidney transplantation using rituximab

 

Low dose MMF

Conventional dose MMF

p1a

p2b

 

Rituximab(+)

Rituximab(+)

Rituximab(−)

 

Group 1 (n = 72)

Group 2 (n = 67)

Group 3 (n = 87)

Sex (male/female)

34/38

42/25

46/41

0.088

0.526

Age (years)

40.92 ± 10.20

44.88 ± 11.65

42.72 ± 10.39

0.034

0.273

Dialysis (hemo/peritoneal)

50/13

57/6

54/13

0.134

1.000

Dialysis duration (months)

24.95 ± 30.20

32.11 ± 33.47

31.04 ± 39.09

0.210

0.324

Etiology of ESRD

   

0.043

0.006

 Diabetes mellitus

13

14

21

  

 Hypertension

11

12

23

  

 Glomerulonephritis

33

16

14

  

 Vesicoureteral reflux

0

4

1

  

 Polycystic kidney disease

3

5

5

  

 Unknown etiology

11

11

15

  

 Other causes

1

5

7

  

Past medical history

     

 Diabetes mellitus

14

15

23

0.682

0.348

 Hypertension

59

57

73

0.655

0.833

 Hepatitis

4

6

2

0.522

0.411

 Autoimmune disease

3

0

1

0.246

0.329

 Malignancy history

1

3

0

0.352

0.453

Mean follow up time (months)

14.89 ± 6.01

12.63 ± 7.59

14.05 ± 8.17

0.053

0.455

ABO compatibility/T-flow

   

0.255

 

 ABO incompatible

47

36

-

  

/T-flow(−)

 ABO compatible

14

21

-

  

/T-flow(+)

 ABO incompatible

11

10

-

  

/T-flow(+)

Donor to recipient

   

0.159

 

 Compatible

14

21

87

  

 A → B

6

11

-

  

 B → A

9

8

-

  

 A/B → O

24

18

-

  

 AB → A/B/O

19

9

-

  

HLA mismatch

3/7/13/14/10/19/6

4/0/7/20/7/18/11

4/2/12/25/14/19/11

0.065

0.335

(0/1/2/3/4/5/6)

HLA class I mismatch

5/14/25/16/12

4/5/27/14/17

5/8/34/23/17

0.260

0.441

(0/1/2/3/4/)

HLA class II mismatch

13/32/27

6/33/28

10/49/28

0.296

0.275

(0/1/2/)

Donor sex (male/female)

39/33

34/33

46/41

0.735

0.875

Donor age (years)

39.63 ± 10.95

41.88 ± 11.65

43.00 ± 9.90

0.241

0.043

Donor’s relation with recipient

   

0.822

0.011

 Parents

8

7

8

  

 Siblings

17

20

36

  

 Children

14

11

6

  

 Spouse

27

21

22

  

 Others

6

8

15

  

CMV IgG serostatus

   

0.178

0.590

 Donor+/Recipient+

70 (97.2 %)

65 (97.0 %)

86 (98.9 %)

  

 Donor+/Recipient-

0 (0.0 %)

2 (3.0 %)

0 (0 %)

  

 Donor-/Recipient+

2 (2.8 %)

0 (0.0 %)

1 (1.1 %)

  
  1. Abbreviations: CMV cytomegalovirus, ESRD end stage renal disease, HLA human leukocyte antigen, MMF mycophenolate mofetil
  2. agroup 1 vs. group 2
  3. bgroup 1 vs. group 3